Renovo Rx Showcases Targeted Oncology Innovation at MedTech Forum
MOUNTAIN VIEW, Calif., November 4, 2025 — RenovoRx, Inc. (NASDAQ: RNXT), a life sciences company pioneering targeted oncology therapies...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
MOUNTAIN VIEW, Calif., November 4, 2025 — RenovoRx, Inc. (NASDAQ: RNXT), a life sciences company pioneering targeted oncology therapies...
MIAMI, November 4, 2025: Pasithea Therapeutics Corp. has announced the activation of a new clinical trial site at the...
CHATHAM, N.J., November 4, 2025: Tonix Pharmaceuticals Holding Corp. has announced a strategic collaboration with Massachusetts General Hospital (MGH)...
Minneapolis, USA, and Brisbane, Australia – November 3, 2025 Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) has announced...
Cambridge, Massachusetts – September 2, 2025 Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene-editing biotechnology company, has nominated EDIT-401,...
Marlborough, Massachusetts – November 3, 2025 Sumitomo Pharma America, Inc. (SMPA) announced compelling new investigational data from multiple clinical...
San Francisco, California – November 3, 2025 Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on harnessing...
MAINZ, Germany, November 3, 2025 — BioNTech SE (Nasdaq: BNTX) reported its third quarter 2025 financial results, highlighting significant...
SAN DIEGO and TORONTO, November 3, 2025 — Aptose Biosciences Inc. (TSX: APS), a clinical-stage precision oncology company, announced...
Yongin, South Korea — November 3, 2025 GC Biopharma has announced promising Phase 2 clinical trial results for its...
